{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:57:09Z","timestamp":1790963829008,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.nmd.2023.02.002","type":"journal-article","created":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T17:36:02Z","timestamp":1677692162000},"page":"324-333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9556-6693","authenticated-orcid":false,"given":"Antje","family":"Mevius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"J\u00f6res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Biskup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Heidbrede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milada","family":"Mahic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Maywald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Lehnerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.nmd.2023.02.002_bib0001","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.nmd.2023.02.002_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261983","article-title":"Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019: a retrospective study using primary care data","volume":"16","author":"Carey","year":"2021","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.nmd.2023.02.002_bib0003","doi-asserted-by":"crossref","first-page":"e01819","DOI":"10.1002\/brb3.1819","article-title":"Epidemiology of myasthenia gravis in Sweden 2006-2016","volume":"10","author":"Westerberg","year":"2020","journal-title":"Brain Behav"},{"issue":"198","key":"10.1016\/j.nmd.2023.02.002_bib0004","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ane.12233","article-title":"Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries","author":"Andersen","year":"2014","journal-title":"Acta Neurol Scand Suppl"},{"issue":"1\u20132","key":"10.1016\/j.nmd.2023.02.002_bib0005","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000500268","article-title":"A Prospective study of the incidence of myasthenia gravis in the east midlands of England","volume":"53","author":"Maddison","year":"2019","journal-title":"Neuroepidemiology"},{"issue":"3\u20134","key":"10.1016\/j.nmd.2023.02.002_bib0006","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000487886","article-title":"Epidemiology of myasthenia gravis in Slovakia in the Years 1977-2015","volume":"50","author":"Martinka","year":"2018","journal-title":"Neuroepidemiology"},{"issue":"3","key":"10.1016\/j.nmd.2023.02.002_bib0007","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/mus.25068","article-title":"Epidemiology of myasthenia gravis in Northern Portugal: frequency estimates and clinical epidemiological distribution of cases","volume":"54","author":"Santos","year":"2016","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.nmd.2023.02.002_bib0008","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/ene.13535","article-title":"A nationwide epidemiological study of myasthenia gravis in Latvia","volume":"25","author":"Zieda","year":"2018","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.nmd.2023.02.002_bib0009","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/joim.12310","article-title":"The autoimmune spectrum of myasthenia gravis: a Swedish population-based study","volume":"277","author":"Fang","year":"2015","journal-title":"J Intern Med"},{"issue":"4","key":"10.1016\/j.nmd.2023.02.002_bib0010","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s00415-015-7963-5","article-title":"Myasthenia gravis: a clinical-immunological update","volume":"263","author":"Binks","year":"2016","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2023.02.002_bib0011","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"10.1016\/j.nmd.2023.02.002_bib0012","doi-asserted-by":"crossref","first-page":"985","DOI":"10.4103\/0301-4738.145987","article-title":"Ocular myasthenia gravis: a review","volume":"62","author":"Nair","year":"2014","journal-title":"Indian J Ophthalmol"},{"issue":"10","key":"10.1016\/j.nmd.2023.02.002_bib0013","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.nmd.2023.02.002_bib0014","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2023.02.002_bib0015","series-title":"Diagnostik und therapie der myasthenia gravis und des lambert-eatonsyndroms","author":"Wiendl","year":"2014"},{"issue":"2","key":"10.1016\/j.nmd.2023.02.002_bib0016","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","article-title":"Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders","volume":"21","author":"Verschuuren","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2023.02.002_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.nmd.2023.02.002_bib0018","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"10.1016\/j.nmd.2023.02.002_bib0019","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/CND.0000000000000257","article-title":"Impact of refractory myasthenia gravis on health-related quality of life","volume":"20","author":"Boscoe","year":"2019","journal-title":"J Clin Neuromuscul Dis"},{"issue":"10","key":"10.1016\/j.nmd.2023.02.002_bib0020","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1002\/acn3.50901","article-title":"Clinical outcome measures following plasma exchange for MG exacerbation","volume":"6","author":"Raja","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"8","key":"10.1016\/j.nmd.2023.02.002_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159993","article-title":"Subcutaneous immunoglobulin therapy in the chronic management of myasthenia gravis: a retrospective cohort study","volume":"11","author":"Bourque","year":"2016","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.nmd.2023.02.002_bib0022","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2023.02.002_bib0023","unstructured":"(KBV), K.B. KBV - Online-version des ebm. 2021 11.10.2021]; Available from: https:\/\/www.kbv.de\/html\/online-ebm.php."},{"key":"10.1016\/j.nmd.2023.02.002_bib0024","unstructured":"BfArM. OPS - Online-version des ops. 2021 11.10.2021]; Available from: https:\/\/www.dimdi.de\/dynamic\/de\/klassifikationen\/ops\/."},{"key":"10.1016\/j.nmd.2023.02.002_bib0025","unstructured":"Fricke, U., J. G\u00fcnther, K. Niepraschk-von Dollen, A. Zawinell, Anatomisch-therapeutisch-chemische klassifikation mit tagesdosen f\u00fcr den deutschen arzneimittelmarkt, W.I.d.A. (WIdO), Editor. 2019."},{"issue":"12","key":"10.1016\/j.nmd.2023.02.002_bib0026","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2023.02.002_bib0027","doi-asserted-by":"crossref","DOI":"10.1177\/1179573521989151","article-title":"A sum score to define therapy-refractory myasthenia gravis: a German consensus","volume":"13","author":"Schroeter","year":"2021","journal-title":"J Cent Nerv Syst Dis"},{"key":"10.1016\/j.nmd.2023.02.002_bib0028","unstructured":"Statistisches Bundesamt. Current population of Germany. 2021 11.10.2021]; Available from: https:\/\/www-genesis.destatis.de\/genesis\/online#astructure."},{"issue":"4","key":"10.1016\/j.nmd.2023.02.002_bib0029","doi-asserted-by":"crossref","first-page":"c379","DOI":"10.1159\/000321525","article-title":"Prediction of mortality in patients undergoing maintenance hemodialysis by Charlson Comorbidity index using ICD-10 database","volume":"117","author":"Chae","year":"2011","journal-title":"Nephron Clin Pract"},{"issue":"11","key":"10.1016\/j.nmd.2023.02.002_bib0030","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1212\/WNL.0000000000008903","article-title":"Clinical and therapeutic features of myasthenia gravis in adults based on age at onset","volume":"94","author":"Cortes-Vicente","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2023.02.002_bib0032","article-title":"Comorbidities in older patients with myasthenia gravis - Comparison between early- and late-onset disease","author":"Klimiec-Moskal","year":"2021","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.nmd.2023.02.002_bib0033","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000012604","article-title":"Patient-reported symptom severity in a nationwide myasthenia gravis cohort: cross-sectional analysis of the Swedish GEMG study","author":"Petersson","year":"2021","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.nmd.2023.02.002_bib0034","first-page":"62","article-title":"Depressive Symptomatik im europ\u00e4ischen Vergleich \u2013 Ergebnisse des European Health Interview Survey (EHIS) 2","volume":"4","author":"Hapke","year":"2019","journal-title":"J Health Monitor"},{"key":"10.1016\/j.nmd.2023.02.002_bib0035","unstructured":"World Health Organization. Depression and other common mental disorders, global health estimates. 2015 10.11.2021]; Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/254610\/WHO-MSD-MER-2017.2-eng.pdf."},{"issue":"1","key":"10.1016\/j.nmd.2023.02.002_bib0036","doi-asserted-by":"crossref","first-page":"19275","DOI":"10.1038\/s41598-022-22078-3","article-title":"Mental health in myasthenia gravis patients and its impact on caregiver burden","volume":"12","author":"Marbin","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.nmd.2023.02.002_bib0037","article-title":"Burden of disease in myasthenia gravis: taking the patient's perspective","author":"Lehnerer","year":"2021","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.nmd.2023.02.002_bib0038","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jocn.2015.01.022","article-title":"Clinical features and impact of myasthenia gravis disease in Australian patients","volume":"22","author":"Blum","year":"2015","journal-title":"J Clin Neurosci"},{"issue":"1","key":"10.1016\/j.nmd.2023.02.002_bib0039","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12883-020-01802-4","article-title":"Prospective study of stress, depression and personality in myasthenia gravis relapses","volume":"20","author":"Bogdan","year":"2020","journal-title":"BMC Neurol"},{"key":"10.1016\/j.nmd.2023.02.002_bib0040","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3389\/fpsyt.2019.00481","article-title":"Risk of depressive disorders following myasthenia gravis: a nationwide population-based retrospective cohort study","volume":"10","author":"Chu","year":"2019","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.nmd.2023.02.002_bib0041","article-title":"Myasthenia gravis: a review of available treatment approaches","volume":"2011","author":"Gilhus","year":"2011","journal-title":"Autoimmune Dis"},{"issue":"3","key":"10.1016\/j.nmd.2023.02.002_bib0042","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin Exp Immunol"},{"issue":"9A","key":"10.1016\/j.nmd.2023.02.002_bib0043","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1590\/0004-282X20130108","article-title":"The myasthenic patient in crisis: an update of the management in Neurointensive Care Unit","volume":"71","author":"Godoy","year":"2013","journal-title":"Arq Neuropsiquiatr"},{"issue":"01","key":"10.1016\/j.nmd.2023.02.002_bib0044","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1055\/s-0043-118441","article-title":"Myasthenia gravis \u2013 exacerbation and crisis","volume":"02","author":"Schroeter","year":"2018","journal-title":"Neurol Int Open"},{"issue":"1","key":"10.1016\/j.nmd.2023.02.002_bib0045","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/1941875210382918","article-title":"Myasthenic crisis","volume":"1","author":"Wendell","year":"2011","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.nmd.2023.02.002_bib0046","doi-asserted-by":"crossref","DOI":"10.1002\/mus.26114","article-title":"Burden of illness in patients with treatment refractory myasthenia gravis","author":"Engel-Nitz","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2023.02.002_bib0047","first-page":"Doc09","article-title":"Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross-sectional analysis of recently approved anti-epileptic drugs","volume":"15","author":"Groth","year":"2017","journal-title":"Ger Med Sci"},{"issue":"1","key":"10.1016\/j.nmd.2023.02.002_bib0048","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12885-020-06738-z","article-title":"Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis","volume":"20","author":"Hardtstock","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.nmd.2023.02.002_bib0049","article-title":"Hospitalized with stroke at the weekend: higher cost and risk of early death?","author":"Ghiani","year":"2021","journal-title":"Int J Stroke"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623000214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896623000214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:13:00Z","timestamp":1760775180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896623000214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0960896623000214"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2023.02.002","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2023.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}